Form D · Biotechnology
Enveda Therapeutics, Inc.
Boulder, CO · CIK 0001821392
Offering snapshot reported Mar 7, 2023 · SEC filing
- Reported sold
- $62.5M Offering amount: $62.5M
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 25, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 7, 2023 | Initial | $62,459,761 | No comparison | 26 | SEC filing |
| Aug 24, 2020 | Initial | $4,999,998 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-475101
Source: Form D, filed Mar 7, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bruce Beutel | Director |
| Viswa Colluru | Director, Executive |
| Zavain Dar | Director |
| Rohit Sharma | Director |
| Shaquille Vayda | Director |
| Daniel Wee | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1880 S Flatiron Ct. Ste. K
Boulder, CO, 80301
Boulder, CO, 80301